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Population-based HIV-free survival at 18–24 months of age among HIV-exposed infants in
high prevalence settings in the era of treatment for all is largely unknown. We conducted a
community-based survey to determine outcomes of HIV-exposed infants at 18–24 months
in Lesotho.
Methods
Between November 2015 and December 2016, we conducted a survey among households
with a child born 18–24 months prior to data collection. Catchment areas from 25 health
facilities in Butha-Buthe, Maseru, Mohale’s Hoek and Thaba-Tseka districts were randomly
selected using probability proportional to size sampling. Consecutive households were vis-
ited and eligible consenting caregivers and children were enrolled.
Rapid HIV antibody testing was performed on mothers of unknown HIV status (never
tested or tested HIV-negative >3 months prior) and their children, and to children born to
known HIV-positive mothers. Information on demographics, health-seeking behavior, HIV,
and mortality were captured for mothers and children, including those who died.
The difference in survival between subgroups was determined using the log-rank test.
Results
Of the 1,852 mothers/caregivers enrolled, 570 mothers were HIV-positive. The mother-to-
child HIV transmission rate was 5.7% [95% CI: 4.0–8.0]. The mortality rate was 2.6% [95%
CI: 1.6–4.2] among HIV-exposed children compared to 1.4% (95% CI: 0.9–2.3) among HIV-
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unexposed children. HIV-free survival was 91.8% [95% CI: 89.2–93.8] among HIV-exposed
infants. Disclosure of mother’s HIV status (aOR = 4.9, 95% CI: 1.3–18.2) and initiation of
cotrimoxazole prophylaxis in the child (aOR = 3.9, 95% CI: 1.2–12.6) were independently
associated with increased HIV-free survival while child growth problems (aOR = 0.2, 95%
CI: 0.09–0.5) were independently associated with reduced HIV-free survival.
Conclusion
Even in the context of lifelong antiretroviral therapy among pregnant and breastfeeding
women, HIV has a significant effect on survival among HIV-exposed children compared to
unexposed children. Lesotho has not reached elimination of HIV transmission from mother
to child.
Introduction
HIV-free survival is the gold standard in measuring the effectiveness of prevention of mother-
to-child HIV transmission (PMTCT) programs especially among breastfeeding populations
[1, 2].
Since 2010, new HIV infections among children have declined by 35%, from 270,000
[170,000–400,000] in 2010 to 160,000 [110,000–260,000] in 2018, demonstrating a nearly 64%
decline since 2001when almost half a million of children were newly infected with HIV [3].
Most of the infections among children remain attributable to mother-to-child transmission
(MTCT) [4, 5]. Program data are now starting to emerge, demonstrating the effectiveness of
these approaches in preventing MTCT using real world data which strengthen global reports
that use modelling data [2, 6–8]. Most of these studies report HIV-free survival before lifelong
antiretroviral therapy (ART) was rolled out.
With an estimated HIV prevalence of 25.6%, Lesotho has the second-highest national HIV
prevalence worldwide [9, 10]. Among antenatal care (ANC) attendees, HIV prevalence ranges
from 5.4% among adolescents aged 15–19 years, to 21.5% among women aged 20–24 years,
37.5% among those aged 25–29 years, and 40% among those aged 30–39 years [11].
Lesotho’s national guidelines recommend that opt-out HIV testing be offered to all preg-
nant women presenting to ANC clinic or in labor with unknown HIV status. If HIV-negative,
women should be retested for HIV at 36 weeks gestation if the prior test was performed� 6
weeks earlier, or if not done prior to delivery, then HIV testing should be done during labor
and delivery [12]. HIV deoxyribonucleic acid polymerase chain reaction (DNA-PCR) or total
nucleic acid (TNA) testing is recommended for infants younger than nine months of age in
Lesotho. Infants with a positive HIV DNA-PCR or TNA test result are initiated on ART imme-
diately while awaiting results of the repeat confirmatory DNA-PCR test. Final documentation
of the child’s HIV status is conducted six weeks following cessation of breastfeeding using HIV
DNA-PCR testing among infants younger than nine months of age, or HIV rapid testing, with
DNA-PCR if the rapid test is positive, among infants and children older than nine months of
age [12].
Traditionally, MTCT rates are assessed at health facility level and focused on six-week
MTCT, though in breastfeeding populations, children are exposed to HIV through breastmilk
for a prolonged period of time [13]. Facility-based HIV-free survival rate estimates are poten-
tially biased because they exclude women and children who do not utilize health facilities espe-
cially in populations where formal health care utilization rates are low. Community-based
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studies to estimate HIV-free survival among HIV-exposed children overcome some bias con-
cerns in facility-based studies. However, since 2013, when the Lesotho Ministry of Health
(MOH) adopted the World Health Organization PMTCT guidelines on universal treatment
[8], no community-based assessment of HIV-free survival has been undertaken in Lesotho.
The Lesotho population-based impact assessment survey found an overall MTCT rate of 2.8%
[14, 15]. We carried out a community household survey to estimate the HIV-free survival of
HIV-exposed children 18–24 months of age after the introduction of lifelong ART.
Materials and methods
Study design
Between November 2015 and December 2016, we conducted a cross-sectional, community-
based survey among households with children born in the previous 18–24 months to estimate
MTCT rates, mortality, HIV prevalence, and HIV-free survival among children.
Sampling procedures
Four districts were purposively selected for the study: Butha-Buthe, Maseru, Mohale’s Hoek,
and Thaba Tseka. The first three districts represent the three national ecological zones: high-
lands, foothills and lowlands. The ecological zones account for variation in overall PMTCT
service delivery coverage and heterogeneity in health-seeking behavior due to changing ter-
rain. Maseru was included as the most populous district in the country. The selection of these
districts was expected to make the sampling nationally representative. Of the 78 facilities across
the four districts, 16 were excluded from the sampling frame, including facilities that were
determined to be difficult to reach (e.g., typically only accessible by helicopter). Within each
district, we used a multi-stage sampling approach to obtain a representative sample of HIV-
positive and HIV-negative mothers and children. First, health facilities from each study district
were randomly selected using probability proportional to size sampling based on the annual
number of live births. Ten facilities from Maseru District and five facilities each from the other
three districts were randomly selected, for a total of 25 facilities. Communities were defined as
the villages within the catchment area of a health facility. In each catchment area, all villages
were assigned a number and then random selection was used to indicate the village from
which recruitment would begin. Recruitment continued according to a pre-determined direc-
tion in the next closest village until the approximated sample size target was obtained. Study
teams recruited participants from all households meeting the inclusion criteria within a village.
If the study team reached approximately half of the target for that catchment area in one vil-
lage, the team then stopped recruitment and moved to the next village to ensure at least two
villages were captured for each catchment area.
To determine the sample size per facility catchment area, we estimated the expected num-
ber of HIV-infected women who had given birth in each area proportionate to the catchment
population size. To identify eligible households within the catchment area, we went door-to-
door or engaged community health workers to identify households in which a mother had
delivered a child 18–24 months prior to data collection. If the mother or a primary caregiver
was not available to complete the survey, a return appointment was made.
Recruitment and enrollment of study population. The study population included moth-
ers and children who were born 18–24 months prior to the data collection time. Household
visits were made by trained research assistants responsible for consenting and data collection,
and HIV counselors responsible for HIV testing. All eligible households were included in the
study if the primary caregiver was willing to provide verbal informed consent. Households
were eligible for study participation, regardless of the vital status of the child (alive/deceased).
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Households were excluded if members of household were not willing to participate, or if the
primary caregiver was less than 18 years and was not the father or mother of the child. House-
holds were visited consecutively, informed about the study, and caregivers were invited to par-
ticipate in the study. If the mother was deceased or was not currently living in the household,
consent for study participation was obtained from the child’s primary caregiver.
Data collection
Caregivers or parents were interviewed in Sesotho or English by research assistants using a
structured data collection tool with responses captured electronically. The questionnaire was
developed specifically for the purpose of this study and collected data needed to answer study
questions. Research assistants first determined the child’s HIV exposure status and then
administered the questionnaire to the mother or caregiver. Information collected from the
questionnaire included demographics, use of health facilities for HIV and maternal and child
health services, maternal HIV status, maternal and infant receipt and use of antiretroviral
drugs during pregnancy and after delivery (if known HIV-positive), infant feeding practices,
and general well-being, including growth and development. The child health card and/or
maternal health card were used to confirm caregiver information. Mortality information for
mothers and children who died was also captured, and attempts were made to determine HIV
status prior to death.
Biologic measurements. During household visits, blood was collected through finger
stick from study participants by a trained community counselor for HIV rapid antibody test-
ing according to the national HIV program testing algorithm. The first test performed was the
Determine™ HIV-1/2 (manufactured by Alere). Participants with a negative Determine™ assay
were told their HIV negative status. All participants who tested positive underwent a second
test (with a new finger prick sample) using Uni-Gold™ Recombigen1HIV-1/2 and were told
their HIV positive status if the second test was also positive. All maternal participants had a
DBS sample taken to be stored in the laboratory for quality control. In addition, DNA-PCR
testing was performed on the DBS sample for all maternal participants to confirm the status
recorded from the field. Further, DBS specimens were collected from all enrolled children for
HIV DNA-PCR confirmatory testing regardless of rapid test results.
All tests conducted for this study were recorded in a log at the testing laboratory using the
unique study identification number. Study laboratory test results were obtained directly from
the laboratory and entered into the study database to link questionnaire responses with labora-
tory results. Study data collectors and investigators reviewed laboratory results and identified
discordant or confirmatory results that required follow-up by the HIV counselors.
Sample size calculation and data analysis
Based on previous PMTCT evaluation studies in Rwanda and Malawi, we expected HIV-free
survival among 18-24-month-old HIV-exposed infants would be lower than the estimate from
Rwanda (91.1%) due to less extensive PMTCT coverage in Lesotho in comparison to Rwanda
[16]. Assuming HIV-free survival in Lesotho was about 85%, we needed 545 HIV-exposed
infants to estimate HIV-free survival with ±3% precision. Adjusting the sample size by 10% for
miscellaneous events (e.g., missing data, consent to some but not all study activities) we tar-
geted to enroll 600 HIV-exposed infants. Given the HIV prevalence of approximately 25.4%
among pregnant women in ANC, we would need to visit or approach 2,363 households with
children in the 18-24-month age range to identify 600 HIV-exposed infants. To account for
potentially 15% refusal rate to participate in the study and interviews with non-maternal care-
givers of HIV-exposed children (who may not be able to adequately answer questions needed
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to address the research aims) we needed to visit approximately 2,700 households to reach the
required sample of HIV-exposed infants and their mothers.
We summarized categorical variables using frequencies and percentages. Continuous vari-
ables were summarized using means and standard deviations, or medians and interquartile
ranges as appropriate. We estimated HIV-free survival as the proportion of children alive and
HIV negative among all HIV-exposed children. The precision around survival estimates was
summarized using 95% confidence intervals. We used the log-rank test to determine whether
there were differences in HIV-free survival between subgroups. Comparisons included HIV-
infected versus HIV-exposed but uninfected children; and HIV-exposed versus HIV-unex-
posed children. Type I error rate (α) for statistical tests was set at 0.05. We performed complete
case analysis, and missing data were not imputed.
We used multivariate logistic regression models to test the independent association of ANC
attendance, mode and place of delivery, gestational age at birth, birth weight, maternal vital
status, adherence to and timing of initiation of antiretroviral drugs, infant feeding method and
nutritional status with HIV-free survival among HIV-exposed children. All statistical data
analysis was performed using STATA version 14.2 (Stata Corp).
Ethical considerations
The study was approved by the Lesotho MOH Research and Ethics Committee and the George
Washington University’s Office of Human Research. All participants were informed of the
study objectives, were given the opportunity to ask questions and provided verbal informed
consent to participate in the study.
Once a household was determined to meet the eligibility criteria, the mother/caregiver of the
eligible child was identified and informed about the evaluation. The verbal informed consent text
included statements that described the purpose of the evaluation, the activities to be conducted
and confidentiality protections, in addition to a specific statement for mothers/caregivers to pro-
vide consent for themselves and their children (if applicable). The interviewer read each of these
statements in the participants’ language of choice (English or Sesotho) exactly as written and doc-
umented the response on an electronic device used for data collection with a password verification
process. The mother/caregiver had the opportunity to ask questions regarding enrollment into
the evaluation. The consent process was structured so that a participant could agree to participate
in some activities, but not others. Biological mothers were the preferred participants, but if the
mother was deceased or not currently living in the household, consent was obtained from the
child’s primary caregiver, who was asked to respond to questions to the extent possible.
Results
Between November 2015 and December 2016, we screened 11,169 households for the study
eligibility (Fig 1). Of the 2,190 eligible households, 1,852 mothers/caregivers consented and
were enrolled in the study. Of the 338 households that declined to participate, the following
reasons were provided: caregiver, child or both were unavailable (n = 178), (157 of whom were
at work); lack of time to participate (n = 71); no incentive provided (n = 25); not comfortable
to participate (n = 16); caregiver did not feel they had enough information to answer questions
(n = 15); mother needed husband’s permission (n = 9); caregiver was below 18 years of age
(n = 6); and other reasons (n = 18).From the enrolled households, there were 1,884 deliveries
(including 66 twin births) that occurred 18–24 months prior to data collection. Most of the
children (77.1%, n = 1,428) were being cared for by their biological mothers. Nearly a third
(30.7%) of biological mothers reported and knew their HIV-positive status. Thirty-nine moth-
ers were newly diagnosed HIV-positive during the study, of whom 38 had previously tested
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HIV-negative during the index pregnancy. A total of 1,199 (64.7%) biological mothers were
HIV-negative and 83 mothers were of unknown HIV status and unavailable for testing.
Characteristics of caregivers
The mean age (±SD) of mothers was 27.8 ± 6.1 years (Table 1). Overall, 95.8% of mothers
attended ANC at least once with over 80% of women delivering in health facilities. One-fifth
(20.8%) of mothers presented with known HIV status at ANC. Most HIV-positive mothers
(94.7%) disclosed their HIV status with 59.9% disclosing it to their spouse or partner.
Characteristics of children
The child participants included 64 twins (3.4%) and 52.5% of the children were male (Table 2).
Preterm births occurred in 9.1% of children, with HIV-exposed children slightly more likely to
have a preterm birth. Overall, 95.2% of infants were ever breastfed, with a breastfeeding rate of
90.7% among HIV-exposed infants. The mean (SD) birth weight was 3.0 (0.5) with HIV
exposed infants having slightly lower mean birth weight compared to HIV unexposed infants.
HIV-unexposed infants were breastfed longer with a mean of 15 months compared to HIV-
exposed infants, who were breastfed for a mean of 11 months.
Fig 1. Participants screening, enrollment, and outcomes.
https://doi.org/10.1371/journal.pone.0237409.g001
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There were 37 reported child deaths, 16 of whom were from HIV-positive mothers. Thirty-
three children were identified as HIV-positive within the participating households among
whom 10 were newly diagnosed during the study. Of the ten children who were newly diag-
nosed with HIV, five had previously tested HIV-negative, three were from known HIV-posi-
tive mothers but had never been tested, and two were from mothers who were newly
diagnosed during the study.
Maternal use of antiretroviral therapy. Overall, 86.8% of HIV-positive women used
ART during pregnancy. Based on child HIV status, 87.4% and 71.4% of mothers of HIV-unin-
fected children and HIV-infected children were enrolled on ART respectively (Table 3). Most
mothers (89.1%) initiated ART either before or during pregnancy. Among mothers of HIV-
infected children, 37.6% started ART either during or after breastfeeding period compared to
9.6% of mothers of HIV-uninfected children. At the time of the study, 88.0% of HIV-positive
mothers reported currently taking ART. Among HIV-exposed children, 89.3% received nevi-
rapine prophylaxis within three days of delivery. Of the 13 HIV-infected children who had rec-
ords about their treatment initiation, 12 were initiated on ART.
Mortality, HIV transmission, and HIV-free survival among children
Tables 4 and 5 summarize child outcomes by HIV exposure status. The estimated child mortal-
ity was 2.6% (95% CI: 1.6–4.2) among HIV-exposed children compared to 1.4% (95% CI: 0.9–













Mean Age (SD) 26.7 (5.9) 30.1 (6.0) 27.7 (5.2) 27.8 (6.1)
Attended ANC during pregnancy 1152 (96.4) 530 (94.8) 56 (93.3) 1738 (95.8)
Mean gestational age in weeks at first ANC (SD) 16.7 (7.5) 16.6 (7.9) 14.7 (8.1) 16.7 (7.6)
Attended 4+ ANC visits 710 (70.6) 302 (68.8) 7 (53.8) 1019 (70.0)
Child delivered at a health facility 934 (81.1) 416 (78.5) 45 (83.3) 1395 (80.4)
Mother known HIV-positive during pregnancy - 114 (20.8) - 114 (6.6)
Mother tested for HIV during pregnancy 1161 (98.1) 418 (73.3) 8 (80.0) 1587 (85.7)
Mother disclosed HIV status to anyone 918 (79.7) 514 (94.7) - 1432 (84.3)
Mother disclosed HIV status to spouse/partner 706 (76.9) 308 (59.9) - 1014 (70.8)
Mother disclosed HIV status to other family members 362 (39.4) 373 (72.6) - 735 (51.3)
Mother disclosed HIV status to others 4 (0.4) 26 (5.1) - 49 (3.4)
https://doi.org/10.1371/journal.pone.0237409.t001












Twin 34 (2.8) 30 (5.1) 0 (0) 64 (3.4)
Male 609 (50.5) 324 (55.7) 56 (59.0) 989 (52.5)
Stillbirth 4 (0.3) 2 (0.3) 2 (2.1) 8 (0.4)
Preterm birth 106 (9.0) 54 (9.9) 3 (3.6) 163 (9.1)
Mean birth weight (SD) 3.05 (0.5) 2.9 (0.6) 3.06 (0.4) 3.02 (0.5)
Child ever breastfed 1169 (97.6) 519 (90.7) 81 (91.0) 1769 (95.2)
Child still breastfeeding after 18 months 200 (17.1) 47 (9.1) 3 (3.7) 250 (14.1)
Median time child was breastfed (IQR) (months) 15 (10–18) 11 (6–14) 12 (6–16) 12 (7–18)
https://doi.org/10.1371/journal.pone.0237409.t002
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2.3) among HIV-unexposed children. The estimated HIV transmission was 5.7% (95% CI:
4.0–8.0). HIV-free survival was 91.8% (95% CI: 89.2–93.8). The majority of child deaths
occurred after the neonatal period (Table 5).
Factors associated with HIV-free survival among children. Table 6 summarizes factors
associated with mortality, HIV transmission and HIV-free survival among children. Disclo-
sure of mother’s HIV status (aOR = 4.9, 95% CI: 1.3–18.2) and initiation of cotrimoxazole pro-
phylaxis in child (aOR = 3.9, 95% CI: 1.2–12.6) were independently associated with increased
HIV-free survival while child growth problems (aOR = 0.2, 95% CI: 0.09–0.5) was indepen-
dently associated with reduced HIV-free survival.









Total HIV-exposed children (N = 396)
Mother had a CD4 test done when pregnant 282 (83.7) 12 (75.0) 294 (85.3)
Missing 30 3 33
Mother received ART during this pregnancy 285 (87.4) 10 (71.4) 295 (86.8)
Missing 41 5 46
Medicine received by mothers who took antiretroviral drugs during pregnancy�
AZT 16 (5.7) 0 16 (5.5)
ART for life 261 (92.9) 10 (100.0) 271 (93.1)
Other 4 (1.4) 0 4 (1.4)
Missing 4 0 4
Time mothers started taking ART�
Before pregnancy with this child 131 (39.5) 4 (25.0) 135 (38.8)
During pregnancy with this child 169 (50.9) 6 (37.5) 175 (50.3)
During breastfeeding of this child 20 (6.0) 5 (31.3) 25 (7.2)
After breastfeeding of this child 12 (3.6) 1 (6.3) 13 (3.7)
Missing 35 3 38
Regimen taken by the mother during pregnancy†
TDF+3TC+EFV 204 (80.3) 8 (80.0) 212 (80.3)
TDF+3TC+NVP 16 (6.3) 2 (20.0) 18 (6.8)
AZT+3TC+EFV 10 (3.9) 0 10 (3.8)
AZT+3TC+NVP 21 (8.3) 0 21 (8.0)
Other 3 (1.2) 0 3 (1.1)
Missing 7 0 7
Mother currently taking ART 313 (88.2) 16 (84.2) 329 (88.0)
� Total N is among those who received antiretroviral drugs during pregnancy
†Total N is among those who received ART for life
https://doi.org/10.1371/journal.pone.0237409.t003









Child mortality 1.4 [0.9–2.3] 2.6 [1.6–4.2] 1.8 [1.3–2.5]
HIV infection - 5.7 [4.0–8.0] -
HIV-free survival - 91.8 [89.2–93.8] -
https://doi.org/10.1371/journal.pone.0237409.t004
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Discussion
We found that HIV-free survival in Lesotho was 91.8%. Our results demonstrate the effective-
ness of the Lesotho PMTCT program in averting HIV infection and deaths in children within
the first 18–24 months of life after introduction of lifelong ART for all HIV-positive pregnant
women in 2013. Our finding corroborates with a systematic review of 18 studies published
between 2005 and 2015, that estimated HIV-free survival in a breastfed population found that
Table 5. Timing of children’s death by HIV exposure (N = 28).









Day 0 4 (26.7) 0 2 (100) 6 (21.4)
Within 24 hours 1 (6.7) 1 (9.1) 0 2 (7.2)
Within 28 days 3 (20.0) 3 (27.3) 0 6 (21.4)
More than 28 days 7 (46.6) 7 (63.6) 0 14 (50.0)
https://doi.org/10.1371/journal.pone.0237409.t005
Table 6. Factors associated with child mortality, HIV transmission and HIV-free survival.
Variable Unadjusted OR [95% CI] p-value Adjusted OR [95% CI] p-value
Factors Associated with Infant Mortality
Infant was a twin (ref = No) 7.1 [3.0–16.8] 0.00 1.4 [0.2–8.7] 0.70
Mother HIV-positive (ref = Negative) 1.9 [0.9–3.7] 0.09 2.0 [0.6–6.8] 0.25
Child delivered in health facility (ref = No) 0.3 [0.1–0.5] 0.00 0.3 [0.1–1.0] 0.06
Timing of child birth (ref = before time) 0.3 [0.1–0.9] 0.02 0.5 [0.1–2.0] 0.32
Mother told child had a growth problem (ref = No) 4.0 [1.5–10.6] 0.01 2.8 [0.8–9.8] 0.11
Child ever breastfed (ref = No) 0.1 [0.0–0.2] 0.00 0.2 [0.0–0.9] 0.04
Infant breastfed for more than 6 months (ref = No) 0.2 [0.1–0.5] 0.00 0.7 [0.2–2.9] 0.60
Factors Associated with HIV Infection
Disclosed HIV test result (ref = no) 0.3 [0.1–0.9] 0.04 0.3 [0.1–1.7] 0.18
Mother told child had a growth problem (ref = no) 2.6 [1.1–6.4] 0.03 4.6 [1.5–13.5] 0.01
Breastfeeding for 6+ months (ref = no) 2.3 [0.9–5.6] 0.06 2.3 [0.8–6.5] 0.12
Started ART (ref = before BF)
During pregnancy 1.5 [0.5–4.4] 0.49 1.2 [0.4–3.9] 0.75
During breastfeeding 9.3 [2.6–32.9] 0.00 3.2 [0.6–15.9] 0.16
Not on ART/After breastfeeding 6.3 [1.8–22.2] 0.00 1.9 [0.2–17.0] 0.57
Received ART throughout breast feeding (ref = yes) 0.3 [0.1–0.8] 0.01 2.2 [0.4–12.8] 0.38
Child was given first dose of NVP syrup within 3 days after delivery (ref = no) 0.3 [0.1–0.6] 0.00 0.3 [0.1–1.1] 0.08
Child was given CTX to take daily beginning at 6 weeks (ref = no) 0.2 [0.1–0.6] 0.00 0.4 [0.1–1.5] 0.18
Factors Associated with HIV-free Survival
Disclosed HIV test result (ref = no) 2.9 [1.0–8.1] 0.04 4.9 [1.3–18.2] 0.017
Delivered in a facility (ref = no) 2.3 [1.4–4.7] 0.00 1.7 [0.7–4.2] 0.22
Mother told child had a growth problem (ref = no) 0.2 [0.1–0.5] 0.00 0.2 [0.1–0.5] <0.01
When started ART (ref = before BF)
During pregnancy 0.7 [0.3–1.6] 0.39 0.7 [0.3–1.8] 0.44
During breastfeeding 0.1 [0.0–0.4] 0.00 0.3 [0.1–1.3] 0.11
Not on ART/After breastfeeding 0.2 [0.1–0.6] 0.01 0.7 [0.1–4.2] 0.69
Received ART throughout breast-feeding (ref = yes) 2.8 [1.3–5.9] 0.01 0.4 [0.1–1.8] 0.26
Child was given first dose of NVP syrup within 3 days after delivery (ref = no) 4.0 [2.2–7.5] 0.00 2.1 [0.6–7.0] 0.22
Child was given CTX to take daily beginning at 6 weeks (ref = no) 5.4 [2.7–10.8] 0.00 3.9 [1.2–12.6] 0.02
https://doi.org/10.1371/journal.pone.0237409.t006
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18-month HIV-free survival estimates were 89.0% (95% CI 83.9%, 94.2%) with maternal ART
for six months (five studies) and 96.1% (95% CI: 92.8%-99.0%) with maternal lifelong ART
(three studies) [17]. HIV-free survival at 24 months was 89.2% (95% CI: 79.9%-98.5%) for chil-
dren whose mothers were on ART for six months (two studies) [17]. Among breastfed infants,
HIV-free survival ranged from 87% (95% CI: 78%-92%) to 96% (95% CI: 91%-98%).
Similarly, in a study in Eswatini, that reported HIV-free survival prior to the era of lifelong
ART for pregnant and breastfeeding women in that country, HIV-free survival was 95.9%
(95% CI: 94.1–97.2) though the authors reported a low death rate due to cultural sensitivities
in collecting death data which may have impacted overall HIV-free survival [8].
Although approaching elimination, the MTCT rate estimated in our study was 5.7% [95%
CI 4.0–8.0]. In the context of Lesotho, this shows much progress compared to the UNAIDS
MTCT rates reported to be 12.7% (9.9–14.4) in 2019, and 30% in 2004 [18]. As UNAIDS esti-
mates are based on models, which make assumptions that may not be accurate, estimates from
surveys like ours are more reliable. The current UNAIDS estimates were based on PMTCT
coverage of 77% (59–89) and early infant diagnosis coverage of 70% (60–90) (15). Further,
assuming all children who died were HIV-infected, the percentage of children who died or were
HIV infected was 8.2% [95%CI 6.2–10.8] versus 12.7% (9.9–14.4) for UNAIDS transmission.
Although mortality among HIV-infected children is high, at most only 50% of HIV-infected
children will die by their second birthday making it unlikely that all children who died were
HIV-infected [4–7]. However, much needs to be done to ensure women living with HIV are
diagnosed even ahead of their index pregnancy or ideally ahead of their first pregnancy because
women who start ART before pregnant and are virally suppressed are less likely to transmit
HIV to their babies in utero, perinatally or through breastfeeding. The MTCT rate in Lesotho
remains unacceptably high, and over three years after the rollout of lifelong ART for HIV-posi-
tive pregnant women, the program has not yet achieved elimination (an MTCT rate of< 5%
and 2% in breastfeeding and non-breastfeeding population respectively) [19]. In addition, our
study shows differences between MTCT rates reported from clinical trials and real world rates.
Former studies have consistently reported MTCT rates lower than 5% [18, 20, 21].
One-third of HIV-infected children were diagnosed during the study. Eight of the ten chil-
dren have been in contact with health system for various services. However, contrary to the
recommendation that all HIV-exposed children should have the final HIV test at 18–24
months or six weeks after cessation of breastfeeding, this was not the case for the eight children
[8]. Five out of ten had tested HIV-negative initially but had not had subsequent test, while
three children whose mothers were on ART had never been tested. This finding shows a need
to look for HIV-infected children beyond PMTCT setting. In a systematic review of 26 papers,
Cohn et. al found that HIV prevalence was highest in pediatric inpatient settings (21.1%, 95%
CI: 14.9–27.3), nutrition centers (13.1%, 95% CI: 3.4–22.7), immunization centers (3.3%, 95%
CI: 0–6.9), then pediatric outpatient (2.7%, 95% CI: 0.3–5.2). Symptom-triggered universal
testing in pediatric outpatient settings had a diagnostic yield similar to that found in the inpa-
tient ward (21.3%, 95% CI: 11.6–31.0 in triggered testing vs 20.9%, 95% CI: 13.5–28.3 in uni-
versal testing) [22]. In a recent paper, data from Cameroon showed nontraditional PMTCT
entry points [adjusted odds ratio (aOR): 1.95; 95% confidence interval (CI): 1.36 to 2.80] was
independently associated with HIV positivity among HIV-exposed children [23]. In a high
prevalence country like Lesotho, optimizing testing with screening of all HIV-exposed chil-
dren at 18–24 months who do not have final HIV status will assist in diagnosing more
children.
Our study also explored factors associated with MTCT and/or death. Factors associated
with MTCT are well elucidated in the literature [22, 24, 25]. Factors associated with HIV-free
survival in Lesotho included HIV-positive mothers disclosing their HIV status and HIV-
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exposed infants taking cotrimoxazole prophylaxis. It can be hypothesized that women who dis-
closed their HIV status got more support to be adherent to their treatment [26, 27]. HIV-
exposed infants who had growth difficulties were more likely to be HIV-infected and/or to die.
The limitations of the study include the fact that information for more than a quarter of
children was received from caregivers who were not biological mothers. Although the team
took all measures to verify the information in the handheld health records, in some instances
such information was not available. However, our results remain valid considering the large
sample size, which took these challenges into consideration.
In addition, for several deceased children, we did not know their HIV status and the cause
of death was not recorded in any home-kept document. This limitation did not have impact
on our results because the study was measuring HIV-free survival and was not set to describe
HIV-related deaths.
Although the data collection was completed almost five years ago, the results of this study
remain relevant especially because it is the first and so far the only community-based survey
carried out in Lesotho to measure HIV-free survival.
Conclusion
Even in the context of lifelong ART among pregnant and breastfeeding women, HIV has a sig-
nificant effect on survival among exposed children. HIV transmission to mothers and children
continue to occur during breastfeeding period, therefore it is important to test mother-child
pairs during the breastfeeding period while they attend routine clinics such as postnatal care,
immunization clinics, outpatient and inpatient services. This study has shown that Lesotho has
not reach elimination MTCT despite introduction lifelong ART for all HIV-positive women.
Since this study measures the effectiveness of PMTCT program when the guidelines were just
changed, it is expected that the performance of program will continue to improve to reach the
MTCT elimination level.
We recommend that the MOH develop a national registry that links HIV-exposed infants
with their mother until final HIV status is ascertained at 18–24 months as per national guide-
lines. In addition, there is a need to repeat this study and triangulate data to measure impact of
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